# Safety and Efficacy Study of Inhaled AmBisome for Prevention of Aspergillus Colonization in Lung Transplant Recipients

> **NCT01254708** · PHASE2 · SUSPENDED · sponsor: **University Health Network, Toronto** · enrollment: 4 (estimated)

## Conditions studied

- Lung Transplant Recipient

## Interventions

- **DRUG:** Ambisome ®
- **DRUG:** Regular standard of care medication

## Key facts

- **NCT ID:** NCT01254708
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2012-01
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 4 (ESTIMATED)
- **Why stopped:** Study has been placed on hold due to unavailability of funding.
- **Last updated:** 2011-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01254708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01254708, "Safety and Efficacy Study of Inhaled AmBisome for Prevention of Aspergillus Colonization in Lung Transplant Recipients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01254708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*